ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results

Benzinga Earnings
11/06

ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.

The company posted quarterly losses of 36 cents per share which missed the analyst consensus estimate of losses of 31 cents per share. The company reported quarterly sales of $37.710 million which missed the analyst consensus estimate of $41.992 million.

“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each,” said Donn Casale, President and Chief Executive Officer of ARS Pharma. “Market share grew where our field team engaged; operating expenses were in line with guidance, including a 42% reduction in third-quarter SG&A expenses from the first-half 2026 quarterly average; and ARS-2 is on track for interim Phase 2b data in the first quarter of 2027.”

ARS Pharmaceuticals shares jumped 5.6% to $2.80 in pre-market trading.

These analysts made changes to their price targets on ARS Pharmaceuticals following earnings announcement.

  • Raymond James analyst Ryan Deschner downgraded the stock from Strong Buy to Outperform and lowered the price target from $28 to $17.
  • Cantor Fitzgerald analyst Josh Schimmer maintained the stock with an Overweight rating and lowered the price target from $30 to $20.

Considering buying SPRY stock? Here’s what analysts think:

Photo via Shutterstock

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10